» Authors » Mathilda Mandel

Mathilda Mandel

Explore the profile of Mathilda Mandel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 670
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Achiron A, Falb R, Menascu S, Magalashvili D, Mandel M, Sonis P, et al.
Neurobiol Dis . 2024 Mar; 194:106475. PMID: 38521093
Background: Relapsing-remitting multiple sclerosis (RRMS), a common demyelinating disease among young adults, follows a benign course in 10-15% of cases, where patients experience minimal neurological disability for a decade following...
2.
Achiron A, Mandel M, Dreyer-Alster S, Magalashvili D, Menascu S, Warszawer Y, et al.
Mult Scler Relat Disord . 2023 Mar; 72:104616. PMID: 36933299
Background: The impact of disease-modifying therapies on the efficacy to mount appropriate immune responses to COVID-19 vaccination in patients with multiple sclerosis (MS) is currently under investigation. Objective: To characterize...
3.
Menascu S, Siegel-Kirshenbaum M, Dreyer-Alster S, Warszawer Y, Magalashvili D, Dolev M, et al.
Mult Scler J Exp Transl Clin . 2023 Jan; 9(1):20552173221151127. PMID: 36687367
Background: Relapsing-remitting multiple sclerosis (RRMS) affects predominantly young women within reproductive years. As an increased risk of relapses is known to occur during the post-partum period, it is important to...
4.
Gurevich M, Zilkha-Falb R, Sonis P, Magalashvili D, Dolev M, Mandel M, et al.
Pediatr Allergy Immunol . 2022 Oct; 33(10):e13863. PMID: 36282137
Background: Studies of anti-SARS-CoV-2 humoral and adaptive response in COVID-19 non-vaccinated pediatric convalescents are controversial and further evidence from the pediatric population are needed. Objectives: To elucidate SARS-CoV-2 humoral and...
5.
Volfovitch Y, Tsur A, Gurevitch M, Novick D, Rabinowitz R, Mandel M, et al.
Immunol Res . 2022 Oct; 70(6):817-828. PMID: 36222965
Coronavirus disease 2019 (COVID-19) is associated with immune dysregulation, severe respiratory failure, and multiple organ dysfunction caused by a cytokine storm involving high blood levels of ferritin and IL-18. Furthermore,...
6.
Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, et al.
J Neuroimmunol . 2022 Sep; 372:577966. PMID: 36162338
Introduction: Cladribine is an effective immunomodulatory treatment used for relapsing forms of multiple sclerosis (MS). Objectives: To describe the clinical outcomes and rates of no evidence of disease activity (NEDA)...
7.
Achiron A, Mandel M, Gurevich M, Dreyer-Alster S, Magalashvili D, Sonis P, et al.
J Neurol . 2022 Mar; 269(5):2286-2292. PMID: 35235002
Background: The majority of multiple sclerosis [MS] patients treated with fingolimod fail to develop a protective level of IgG humoral and adaptive cellular immune responses following full BNT162b2 SARS-CoV-2 vaccination....
8.
Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, et al.
J Neurol Sci . 2022 Jan; 434:120155. PMID: 35091386
Background: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks...
9.
Gurevich M, Zilkha-Falb R, Sonis P, Magalashvili D, Menascu S, Flechter S, et al.
Int J Infect Dis . 2021 Dec; 115:208-214. PMID: 34896265
Objectives: Antiviral adaptive immunity involves memory B cells (MBC) and memory T cells (MTC). The dynamics of MBC and MTC in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescents warrant...
10.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Gurevich M
Eur J Intern Med . 2021 Nov; 94:105-107. PMID: 34742628
No abstract available.